Skip to main content
رجوع
CORT logo

Corcept Therapeutics Incorporated

جودة البيانات: 100%
CORT
NASDAQ Healthcare Biotechnology
KWD 40.47
▲ KWD 6.65 (19.66%)
القيمة السوقية: 4.30B
نطاق اليوم
KWD 34.01 KWD 50.37
نطاق 52 أسبوعًا
KWD 28.66 KWD 117.33
حجم التداول
11,718,296
متوسط 50 يوم / 200 يوم
KWD 37.45 / KWD 64.86
الإغلاق السابق
KWD 33.82

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E 43.2 0.2
P/B 6.7 3.0
ROE % 15.0 3.6
Net Margin % 13.1 3.8
Rev Growth 5Y % 20.1 9.7
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 68.40 +69.0%
Low: KWD 30.00 High: KWD 100.00
مكرر الربحية المستقبلي
113.27
ربحية السهم المستقبلية
KWD 0.36
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
884.47M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 8.40
KWD 7.62 – KWD 9.46
 2.56B 1
FY2029 KWD 6.13
KWD 5.56 – KWD 6.90
 2.12B 1
FY2028 KWD 2.89
KWD 2.15 – KWD 4.09
 1.53B 3

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-24 KWD 0.33 KWD 0.20 -39.4%
2025-11-04 KWD 0.18 KWD 0.16 -11.1%
2025-07-31 KWD 0.23 KWD 0.29 +26.1%
2025-05-05 KWD 0.17 KWD 0.17 0.0%
2025-02-26 KWD 0.37 KWD 0.26 -29.7%
2024-10-30 KWD 0.28 KWD 0.41 +46.4%
2024-07-29 KWD 0.23 KWD 0.32 +39.1%
2024-05-01 KWD 0.22 KWD 0.25 +13.6%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

النقاط الرئيسية

Revenue grew 20.10% annually over 5 years — strong growth
Earnings declined -28.68% over the past year
ROE of 15.01% — decent returns on equity
Debt/Equity of 0.01 — conservative balance sheet
Generating 141.79M in free cash flow
P/E of 43.20 — premium valuation

النمو

Revenue Growth (5Y)
20.10%
Revenue (1Y)12.79%
Earnings (1Y)-28.68%
FCF Growth (3Y)5.70%

الجودة

Return on Equity
15.01%
ROIC5.14%
Net Margin13.09%
Op. Margin5.88%

الأمان

Debt / Equity
0.01
Current Ratio2.92
Interest Coverage0.00

التقييم

P/E Ratio
43.20
Forward P/E113.27
P/B Ratio6.65
EV/EBITDA93.55
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12.79% Revenue Growth (3Y) 25.64%
Earnings Growth (1Y) -28.68% Earnings Growth (3Y) -3.10%
Revenue Growth (5Y) 20.10% Earnings Growth (5Y) -2.99%
Profitability
Revenue (TTM) 761.41M Net Income (TTM) 99.65M
ROE 15.01% ROA 11.91%
Gross Margin 98.30% Operating Margin 5.88%
Net Margin 13.09% Free Cash Flow (TTM) 141.79M
ROIC 5.14% FCF Growth (3Y) 5.70%
Safety
Debt / Equity 0.01 Current Ratio 2.92
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 43.20 Forward P/E 113.27
P/B Ratio 6.65 P/S Ratio 5.65
PEG Ratio -1.22 Forward PEG N/A
EV/EBITDA 93.55 Fwd EV/EBITDA 20.56
Forward P/S 4.87 Fwd Earnings Yield 0.88%
FCF Yield 3.29%
Market Cap 4.30B Enterprise Value 4.19B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 761.41M 675.04M 482.38M 401.86M 365.98M
Net Income 99.65M 139.73M 106.14M 101.42M 112.51M
EPS (Diluted) 0.82 1.23 0.94 0.87 0.89
Gross Profit 748.43M 664.16M 475.89M 396.47M 360.70M
Operating Income 44.80M 136.95M 107.28M 112.63M 124.48M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 836.65M 840.55M 621.52M 583.43M 423.76M
Total Liabilities 188.85M 160.96M 114.81M 81.59M 47.95M
Shareholders' Equity 647.81M 679.59M 506.71M 501.84M 375.81M
Total Debt 6.11M 6.94M 151,000.0 1.14M 526,000.0
Cash & Equivalents 120.50M 127.67M 135.55M 66.33M 77.62M
Current Assets 485.46M 471.60M 458.64M 499.25M 266.46M
Current Liabilities 166.09M 140.77M 104.51M 72.49M 47.54M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#1011 of 1049
17

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026